Clinical Trial Update: A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

View source ↗

Summary

A completed clinical trial evaluated the outcomes of adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | Status: COMPLETED | Results posted: 2025-02-04